Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials

Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shou-Bo, Gao, Kai-Di, Jiang, Tao, Cheng, Shu-Jun, Li, Wen-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593645/
https://www.ncbi.nlm.nih.gov/pubmed/28915674
http://dx.doi.org/10.18632/oncotarget.16924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593645/
https://www.ncbi.nlm.nih.gov/pubmed/28915674
http://dx.doi.org/10.18632/oncotarget.16924

Ejemplares similares